The agency’s biopharma, biotech, health tech and consumer science experts weigh in on how the public’s heightened awareness of science affects stakeholders across the entire healthcare continuum.
Purple Biotech Ltd (via Public) / Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219 Collaboration to Study NT219 in Combination with anti-CTLA4 and anti-PD1/PDL1 Antibodies publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.
Message :
Required fields
NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors
Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer REHOVOT, Israel, June 4, 2021 - Purple Biotech Ltd. ( Purple Biotech , or the Company ) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, announced today the presentation of new data from the first dose level cohort of its ongoing Phase 1/2 clinical trial of NT219, at the 2021 ASCO Annual Meeting, being held virtually June 4-8, 2021. The Phase 1/2 study is evaluating NT219 as monotherapy for the treatment of solid tumors, in addition to a subsequent dose escalation of NT219 in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the treatment of recu